| Literature DB >> 32015045 |
Sarah Israel1,2, Hila Elinav2, Ram Elazary3, Daniel Porat4, Roni Gibori4, Arik Dahan4, Carmil Azran5, Ehud Horwitz2,6.
Abstract
Bariatric surgery is increasingly performed in morbidly obese HIV patients. Limited data exist regarding antiretroviral drug exposure after bariatric surgery. We report a case of a morbidly obese HIV patient who underwent sleeve gastrectomy. Abacavir, lamivudine, and dolutegravir therapeutic drug monitoring was performed at several time points pre- and postsurgery. Significantly increased levels were measured, particularly for abacavir, whose levels increased ∼12-fold. Several mechanistic explanations for these findings are discussed.Entities:
Keywords: antiretrovirals; bariatric surgery; obesity; sleeve gastrectomy
Year: 2020 PMID: 32015045 PMCID: PMC7179309 DOI: 10.1128/AAC.02453-19
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191